|Bid||72.450 x 600|
|Ask||72.460 x 300|
|Day's Range||71.740 - 72.580|
|52 Week Range||60.010 - 77.790|
|PE Ratio (TTM)||9.02|
|Forward Dividend & Yield||2.64 (3.68%)|
|1y Target Est||N/A|
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Altria Group, Inc. Here are 5 ETFs with the largest exposure to MO-US. Comparing the performance and risk of Altria Group, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Smoking is one of the world’s favorite pass time activity, whether they’re at work, at home, or away from all the stress of work, so we were curious to find out just which were the biggest tobacco companies in the world in 2017. Smoking isn’t exactly the best practice humans could have picked. On top […]
Of the 15 analysts that follow Altria Group, 53.3% recommend a “buy,” and 46.7% recommend a “hold.” None of the analysts recommend a “sell” option.
For the next four quarters, analysts expect Philip Morris and Altria Group to post EPS growth of 16.5% and 11.1%, respectively.
For the next four quarters, analysts expect Altria to post gross margin, EBITDA margin, and net margin readings of 62.1%, 52.2%, and 33.6%, respectively.
Motley Fool investors offer up McDonald's, Brookfield Infrastructure Partners, and Altria as better income options today.
For the next four quarters, analysts expect Philip Morris International (PM) to post revenues of ~$31.3 billion.
In 3Q17, Philip Morris International (PM) posted net revenues of ~$7.5 billion, which was 3.2% lower than the analyst estimate of ~$7.7 billion.
In 3Q17, Philip Morris posted adjusted earnings per share of $1.27 on revenues of ~$7.5 billion. Altria Group posted adjusted earnings per share of $0.90 on revenues of $5.1 billion.
The U.S. Food and Drug Administration said on Wednesday it is considering measures to speed development of products that help people quit smoking, including easing requirements for approval of over-the-counter nicotine replacement therapies. The agency said it is "re-evaluating and modernizing" its approach to regulating nicotine replacement therapies (NRT), which are typically sold as gums, patches and lozenges. Because their effectiveness is limited, the FDA wants to give consumers a wider range of options.
Nov.29 -- Andre Calantzopoulos, Philip Morris International chief executive officer, discusses the company's bet on smoke-free products with Bloomberg's Kevin Cirilli on "Bloomberg Markets: Balance of Power."